Assembly Biosciences (ASMB) Current Deferred Tax Assets (2017)

Assembly Biosciences (ASMB) recorded quarterly Current Deferred Tax Assets of $4.9 million in Q4 2017.

Assembly Biosciences (ASMB) Current Deferred Tax Assets (2017) Analysis & Trends

Assembly Biosciences' Current Deferred Tax Assets history runs 1 years deep, the most recent figure standing at $4.9 million for Q4 2017.

In Q4 2017, Current Deferred Tax Assets changed N/A year-over-year to $4.9 million; the TTM figure through Dec 2017 stood at $4.9 million (changed N/A YoY), while the FY2017 annual figure was $4.9 million, changed N/A from the prior year.
Current Deferred Tax Assets was $4.9 million for Q4 2017 at Assembly Biosciences.
In the past five years, Current Deferred Tax Assets ranged from a high of $4.9 million in Q4 2017 to a low of $4.9 million in Q4 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Assembly Biosciences	418.96 Mn	192.36 Mn	-

Download Data

Date	Value
Dec 31, 2017	4.90 Mn
Dec 31, 2017	4.90 Mn